Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone858-320-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.25 million
Profitability
Miscellaneous
Employees95
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) posted its quarterly earnings data on Monday, August, 12th. The medical research company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.19. The medical research company had revenue of $1.19 million for the quarter. Biocept had a negative return on equity of 263.98% and a negative net margin of 672.27%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
1 brokers have issued 12-month target prices for Biocept's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Biocept's share price to reach $3.00 in the next year. This suggests a possible upside of 280.9% from the stock's current price. View Analyst Price Targets for Biocept.
What is the consensus analysts' recommendation for Biocept?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.
What are Wall Street analysts saying about Biocept stock?
Here are some recent quotes from research analysts about Biocept stock:
- 1. Maxim Group analysts commented, "Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the balance sheet." (5/9/2019)
- 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019)
Has Biocept been receiving favorable news coverage?
Media coverage about BIOC stock has been trending positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biocept earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Biocept.
Are investors shorting Biocept?
Biocept saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 598,600 shares, a drop of 15.7% from the August 15th total of 710,300 shares. Based on an average trading volume of 450,800 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the company's stock are sold short. View Biocept's Current Options Chain.
Who are some of Biocept's key competitors?
What other stocks do shareholders of Biocept own?
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg, Director of Technology Devel.
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $0.79.
How big of a company is Biocept?
What is Biocept's official website?
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
